Other languages Corcept Therapeutics Incorporated

Equities

CORT

US2183521028

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-13 pm EDT			5-day change	1st Jan Change
31.51 ^USD	-3.46%		-8.61%	-2.99%

01:20pm	Teva Pharmaceutical Sues Corcept Therapeutics Alleging Market Monopolization for Cushing's Syndrome Drug Korlym	MT
Jun. 13	Teva sues Corcept over mifepristone 'monopoly' for rare disorder	RE

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Teva Pharmaceutical Sues Corcept Therapeutics Alleging Market Monopolization for Cushing's Syndrome Drug Korlym	07:20am
DAX zum Mittag: Bewegungen am Aktienmarkt	05:27am
Les gagnants raflent tout	03:02am
En Direct des Marchés : TotalEnergies, Accor, GTT, Atos, Casino, Adobe, Tesla, Tesco...	02:44am
Borsa di Italia: I vincitori prendono tutto	02:00am
Bolsa de Madrid: Los ganadores se lo llevan todo	02:00am
Teva sues Corcept over mifepristone 'monopoly' for rare disorder	Jun. 13
Sector Update: Health Care Stocks Retreat Tuesday Afternoon	May. 28
Corcept Therapeutics Says Phase 3 Hypercortisolism Trial Meets Primary Endpoint; Shares Advance	May. 28
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 Grace Trial of Relacorilant in Patients with Hypercortisolism (Cushing?S Syndrome)	May. 28
Corcept Therapeutics Insider Sold Shares Worth $1,400,000, According to a Recent SEC Filing	May. 16
Corcept Therapeutics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 01
Corcept Therapeutics Incorporated Completes Enrollment in Phase 4 Catalyst Trial	Apr. 29
Corcept Therapeutics Incorporated Announces Positive Results from Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients with Cushing?s Syndrome	Apr. 22
Corcept Completes Enrollment in Phase 2 Dazals Trial in Patients with Amyotrophic Lateral Sclerosis	Apr. 15
Corcept Therapeutics Incorporated Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer	Apr. 08
Corcept Therapeutics Incorporated Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients with Adrenal Cushing's Syndrome	Apr. 01
Corcept Therapeutics Insider Sold Shares Worth $430,475, According to a Recent SEC Filing	Mar. 21
Sector Update: Health Care Stocks Advance Friday Afternoon	Feb. 16
Sector Update: Health Care Stocks Gain Pre-Bell Friday	Feb. 16

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Corcept Therapeutics Incorporated

Equities

CORT

US2183521028

Other languages

Filters